Statement on the Introduction of the House Companion to the Cure Hepatitis C Act
July 21, 2026 — Treatment Action Group (TAG) welcomes the introduction of the House companion to the Cure Hepatitis C Act (S.1941) and applauds Representatives Diana DeGette (D-CO), Mariannette Miller-Meeks (R-IA), Hank Johnson (D-GA), and Don Bacon (R-NE) for advancing bipartisan legislation to eliminate hepatitis C in the United States. We are particularly encouraged…

Treatment Action Group Comment on the Proposed Rule “Regulation for Federal Financial Assistance” (OMB-2026-0034)
July 15, 2026 — Treatment Action Group (TAG) has submitted formal comments opposing a proposed rule from the White House Office of Management and Budget (OMB) that would overhaul how federal research grants are awarded and managed. Under the proposed rule changes, scientific experts would still review research applications, but political appointees would have…

TAG and LAT CAB Welcome Indian Patent Office Decision That Could Expand Access to Hepatitis C Treatment
May 22, 2026 — TAG and the Long-Acting Therapies Community Advisory Board (LAT CAB) welcomed a decision by the Indian Patent Office rejecting a patent application related to the hepatitis C treatment combination glecaprevir/pibrentasvir (G/P). Advocates say the decision could help reduce barriers to generic competition, lower treatment costs, and expand access to hepatitis…

Treatment Action Group Demands End to Political Meddling in NIH Grants
May 21, 2026 — Treatment Action Group (TAG) is profoundly troubled by recent reporting that the NIH’s longstanding Notice of Funding Opportunity (NOFO) process is being interrupted and delayed by political interference.

TAG Executive Director Mark Harrington Receives Wakefield HVTN Award
May 13, 2026 — Huge congratulations to TAG’s Executive Director Mark Harrington for winning a Wakefield Outstanding Dedication Award presented by the HIV Trials Network (HVTN)! The HVTN, the largest publicly funded collaboration facilitating HIV/AIDS vaccine evaluations, presents the Wakefield Award to public health champions who demonstrate exceptional service and contribution to HIV vaccine…

TAG Statement on Results of the PreVenTB Phase III Trial of TB Vaccine Candidates VPM1002 and Immuvac
April 15, 2026 — Well-conducted study sponsored by Indian Council of Medical Research did not meet primary efficacy endpoint of preventing microbiologically confirmed TB disease

The CDC’s Unjustified Halt on Testing for Dangerous Pathogens is Bad for Everyone’s Health – TAG Calls for CDC to Immediately Reinstate Essential Diagnostic Testing
April 8, 2026 — CDC pauses rabies, mpox, and other infectious disease testing amid budget cuts and staffing losses, raising urgent public health concerns.

Treatment Action Group Welcomes Adam Ortega as Communications Director
March 23, 2026 — TAG announced today the appointment of Adam Ortega as Communications Director. Adam brings experience in nonprofit marketing and public health and will lead TAG’s communications strategy to expand its reach and impact, and will deepen TAG as a leading voice in treatment advocacy, research, and community engagement on our work…

TAG Condemns Latest U.S. “Forever” War in the Middle East, Calls for Reprogramming Billions from Military Aggression to Health and Research
March 18, 2026 — TAG condemns the United States’ war in Iran and neighboring countries. At a time when U.S. investment in public health is being slashed, the Trump administration has chosen to spend billions of dollars per day on weapons used in a war of choice for which no credible rationale has been…

2026 CROI Tuberculosis Research Round Up
March 12, 2026 — New tuberculosis research presented at the 2026 Conference on Retroviruses and Opportunistic Infections (CROI) in Denver offers important updates on TB prevention and treatment for people living with HIV. TAG summarizes key findings on short-course preventive therapy, treatment dosing strategies, and emerging long-acting technologies. Read TAG’s analysis.